GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
A5322 Tianeptine sodiumSummary: 5-HT uptake facilitator, antidepressant -
B1879 AdipoRonTarget: AdipoR1|AdipoR2Summary: AdipoR1 and AdipoR2 agonist, first orally active -
B6707 Sphingosine-1-phosphateSummary: endogenous second messenger and ligand for S1PR1 -
C4493 Midodrine (hydrochloride)Summary: prodrug of the α1-adrenergic receptor agonist -
B1951 Hydrocortisone14 CitationSummary: steroid hormone or glucocorticoid -
B1361 Medetomidine HClSummary: Selective α2-adrenoceptor agonist -
B1349 Tetrahydrozoline HClSummary: Adrenergic receptor agonist -
B6491 Rauwolscine hydrochlorideSummary: α2-adrenergic antagonist -
C6723 Theophylline-7-acetic acid -
B7183 Nefazodone hydrochlorideSummary: 5-HT2A receptor antagonist

